# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
HC Wainwright & Co. analyst Swayampakula Ramakanth reiterates IN8bio (NASDAQ:INAB) with a Buy and maintains $14 price ta...
IN8bio's nsCAR platform, INB-300. Presented at AACR 2024, new preclinical data highlights its superior selectivity in targe...
Shares of PriceSmart, Inc. (NASDAQ: PSMT) rose sharply in today’s pre-market trading as the company posted better-than-expecte...
Laidlaw & Co. analyst Yale Jen initiates coverage on IN8bio (NASDAQ:INAB) with a Buy rating and announces Price Target o...